{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:15:25Z","timestamp":1764731725353,"version":"3.41.2"},"reference-count":48,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R36MH127826","T32MH125792"],"award-info":[{"award-number":["R36MH127826","T32MH125792"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To estimate incidence rates of suicidal ideation and behavior following treatment initiation with gabapentinoids or dopamine agonists (DAs) in patients with newly diagnosed early\u2010onset idiopathic restless legs syndrome (RLS) and to examine suicidal behavior risk, comparing between those receiving gabapentinoids and DAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A new user retrospective cohort study using MarketScan claims data from 2012 to 2019 was conducted. Exposures were monotherapy gabapentinoids or DAs initiated within 60\u2009days of new RLS diagnosis. Three varying outcome measures of suicidality were examined and incidence rates were calculated for each. A log\u2010binomial regression model the estimated relative risk (RR) of the outcomes with gabapentinoids. Propensity score weighting adjusted for baseline covariates, including age, substance use disorders, hyperlipidemia, antipsychotic use, hypnotic\/sedative use, and mood stabilizer use, which were most imbalanced before weighting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 6672 patients, with 4986 (74.7%) initiating a DA and 1686 (25.3%) initiating a gabapentinoid. Incidence rates for all outcome measures were higher in the gabapentinoid group (suicidality: 21.6 vs. 10.7 per 1000 person\u2010years; suicidality with self\u2010harm: 23.0 vs. 11.1 per 1000 person\u2010years; overdose\u2010 and suicide\u2010related events: 30.0 vs. 15.5 person\u2010years). Associated risk of suicidality (adjusted RR, 1.27 [95% CI, 0.86\u20131.88]); suicidality with self\u2010harm (adjusted RR, 1.30 [95% CI, 0.89\u20131.90]); or overdose\u2010 and suicide\u2010related events (adjusted RR, 1.30 [95% CI, 0.93\u20131.80]) was not significant with gabapentinoids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Incidence rates for suicidal ideation and behavior were higher among the gabapentinoid group, although increased risk was not detected after adjustment. A possible signal cannot be ruled out given limitations of the data and rarity of the outcome.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5852","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:55:06Z","timestamp":1722840906000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Suicidal Ideation and Behavior Following Early\u2010Onset Idiopathic Restless Legs Syndrome Treatment"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-2712","authenticated-orcid":false,"given":"Brianna","family":"Costales","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, Center for Drug Evaluation and Safety, College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-2160","authenticated-orcid":false,"given":"Scott\u00a0M.","family":"Vouri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, Center for Drug Evaluation and Safety, College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-1021","authenticated-orcid":false,"given":"Joshua\u00a0D.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, Center for Drug Evaluation and Safety, College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-9445","authenticated-orcid":false,"given":"Barry","family":"Setlow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-8720","authenticated-orcid":false,"given":"Amie\u00a0J.","family":"Goodin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, Center for Drug Evaluation and Safety, College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,4]]},"reference":[{"volume-title":"UpToDate","year":"2023","author":"Ondo W.","key":"e_1_2_12_2_1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010019\u201000698\u20101"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11325\u2010011\u20100606\u2010x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.12.026"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2016.06.007"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2018.11.001"},{"volume-title":"UpToDate","year":"2020","author":"Silber M. H.","key":"e_1_2_12_8_1"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2022.05.003"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003388"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2016.01.017"},{"key":"e_1_2_12_12_1","unstructured":"National Vital Statistics System CDC WONDER Online Database \u201cMultiple Cause of Death Files 2018\u20132022 as Compiled From Data Provided by the 57 Vital Statistics Jurisdictions Through the Vital Statistics Cooperative Program \u201d2024 http:\/\/wonder.cdc.gov\/mcd\u2010icd10\u2010expanded.html."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.09.019"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2010.07.007"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.06.016"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.9966"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010017\u20100590\u20106"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.15030055"},{"volume-title":"HORIZANT (Gabapentin Enacarbil) Extended\u2010Release Tablets for Oral Use [Package Insert]","year":"2020","author":"Food and Drug Administration (FDA)","key":"e_1_2_12_19_1"},{"key":"e_1_2_12_20_1","first-page":"1","volume-title":"NEURONTIN\u00ae (Gabapentin) Capsules, for Oral Use [Package Insert]","author":"Food and Drug Administration (FDA)","year":"2020"},{"volume-title":"LYRICA (Pregabalin) Capsules [Package Insert]","year":"2020","author":"Food and Drug Administration (FDA)","key":"e_1_2_12_21_1"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2147"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4979"},{"key":"e_1_2_12_24_1","unstructured":"\u201cMedicaid NADAC (National Average Drug Acquisition Cost) Database \u201d2022 https:\/\/data.medicaid.gov\/dataset\/dfa2ab14\u201006c2\u2010457a\u20109e36\u20105cb6d80f8d93."},{"key":"e_1_2_12_25_1","unstructured":"Food and Drug Administration (FDA) \u201cFDA Approves First Generics of Lyrica \u201d2019 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010generics\u2010lyrica."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115479"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7908"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23430"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/35395"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000634"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001122"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1037\/ser0000099"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291715001804"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.12.003"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000359"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnu.12515"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/33.1.81"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888\u2010022\u201003716\u20106"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010005\u20100604\u20107"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S116271"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28903"},{"volume-title":"Statistical Review and Evaluation Antiepileptic Drugs and Suicdality","year":"2008","author":"Mentari E.","key":"e_1_2_12_43_1"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000242"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535\u20107511.2010.01382.x"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.1988"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3421"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1027\/0227\u20105910\/a000499"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz038"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T01:51:25Z","timestamp":1732153885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/pds.5852"],"URL":"https:\/\/doi.org\/10.1002\/pds.5852","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5852"}}